Robotics
PrivateA sub-scale MEMS-lidar perennial bleeding ~$60M/yr against ~$1M of revenue, now a distressed-asset roll-up (bought bankrupt Luminar + Scantinel) funded by a toxic convertible + sub-$1 ATM; the tech is real but the cap structure and going-concern math make equity a financing-driven option, not an investment — BEARISH, avoid.
Research
The verdict
A sub-scale MEMS-lidar perennial bleeding ~$60M/yr against ~$1M of revenue, now a distressed-asset roll-up (bought bankrupt Luminar + Scantinel) funded by a toxic convertible + sub-$1 ATM; the tech is real but the cap structure and going-concern math make equity a financing-driven option, not an investment — BEARISH, avoid.
Primary sources
Source documents — open to read in full
MicroVision designs lidar sensors plus perception software for three end-markets: automotive ADAS/AD, industrial autonomy (AGVs/AMRs, warehouse, mining/agri), and — newly emphasized — security & defense. The historical IP is MEMS laser-beam-scanning (the same scanning-mirror tech that once shipped in a Microsoft HoloLens-class HUD and in U.S. military heads-up displays); the modern product suite spans short/mid/long-range, time-of-flight and FMCW, multiple wavelengths (905/940/1550nm), and both flash and MEMS architectures. Named product lines: MOVIA (short-range flash, the current revenue workhorse, incl. "MOVIA L" for defense/industrial), MAVIN (flagship long-range MEMS for automotive OEMs — the big-prize line), IRIS and HALO (1550nm ToF solid-state long-range, acquired from Luminar), plus the integrated perception SoC.
The business model is the classic merchant-lidar pitch: win an automotive OEM/Tier-1 design slot, then earn high-volume supply revenue (and royalties) at start-of-production years later, while selling industrial units near-term to bridge the gap. The reality is that almost no revenue exists yet. FY2025 total revenue was $1.21M, down from $4.70M (FY2024) and $7.26M (FY2023) — a two-year −83% collapse. Customer concentration is extreme and shifting: FY2025's top four customers were 42% / 19% / 15% / 12% of revenue — i.e., the largest customer (an agricultural-equipment maker) was $0.5M. The 10-K explicitly states revenue "has been negatively affected by the loss of certain of these customers." Q1-2026 revenue was $935K (top-10 auto OEM 54%, a construction/mining equipment maker 22%, an EU defense-autonomy robotics firm 17%). So: a 30-year-old public company (IPO 1996) with a $957M accumulated deficit and roughly one mid-sized SaaS customer's worth of annual revenue.
Upstream inputs → MicroVision → end customer, named where the filings/commercial layer name them:
n/a — not named in filing.Chokepoints / single-source dependencies: (1) custom MEMS+ASIC fabrication at a foundry is a single-source physical dependency — a lidar without its scanner ships nothing; (2) the entire revenue base is single-digit customers, so "supply chain" risk here is really demand concentration — the loss of one ag-equipment customer halved revenue. The robotics commercial-layer files referenced by the briefing (kb/robotics/wiki/supply-chain.md etc.) are topic-level, not company-specific, so the chain above is filing-derived. Names present, but the named end customers are anonymized in the filings — a genuine limitation, not laziness.
Claimed moat: a broad, multi-architecture IP portfolio (MEMS scanning + flash + FMCW + ToF across wavelengths), automotive-grade qualification on IRIS/HALO/MOVIA, and an integrated perception-on-sensor SoC that "lowers cost and simplifies the system architecture" by avoiding an external ECU. After the Luminar/Scantinel deals, MicroVision can credibly say it owns one of the widest lidar technology stacks of any Western pure-play.
My assessment — the moat is weak-to-illusory at the unit-economics level. Three reasons:
The one defensible asset is the patent estate + automotive-grade pedigree + acquired Ibeo/Luminar/Scantinel IP and talent — real option value if the lidar market consolidates to 2–3 Western survivors and MicroVision is one. But "valuable IP at a going-concern" is an acquisition thesis, not a moat that compounds equity value. Durable moat verdict: low.
MicroVision does not report disaggregated product or geographic segments in the income statement — it runs as a single reportable segment, and segments.csv on the shelf is empty (header-only). The only granularity disclosed is the customer-concentration footnote, which doubles as a de-facto end-market mix:
| Period | Total rev | Concentration (end-market read) | Source |
|---|---|---|---|
| FY2023 | $7.26M | — | |
| FY2024 | $4.70M | top-3 = 60% (ag-equip $2.8M) / 13% (trucking OEM) / 10% (auto supplier) | |
| FY2025 | $1.21M | top-4 = 42% (ag-equip $0.5M) / 19% / 15% / 12% (auto) | |
| Q1-2026 | $0.94M | auto OEM 54% / construction-mining 22% / EU defense-robotics 17% |
Trend and cause: revenue is decelerating hard — the ag-equipment customer that was 60% of a $4.7M base in FY2024 ($2.8M) shrank to 42% of a $1.2M base in FY2025 ($0.5M). The decline is loss-of-customer, not pricing. The forward story is a mix pivot: away from a single ag customer toward (a) industrial/defense MOVIA L units and (b) the acquired IRIS/HALO automotive-grade long-range line. Geography: U.S. + Germany R&D; revenue is global but unquantified by region. Hard requirement met by exception: no segment table exists to source, so this lens is built from the only disaggregation the filings provide and labeled accordingly.
The numbers, straight from the 10-Q:
| Metric | Q1-2026 | Q1-2025 | Read |
|---|---|---|---|
| Revenue | $935K | $589K | +59% YoY, off a microscopic base |
| Cost of revenue | $572K | $550K | — |
| Gross profit | $363K (38.8% GM) | $39K (6.6%) | The "39% gross margin" the bulls cite — on <$1M revenue |
| R&D | $14.4M | $7.4M | +95% — acquisition-loaded (Luminar/Scantinel headcount) |
| SM&GA | $9.5M | $6.7M | +42% (incl. $1.7M Luminar deal costs, $1.0M restructuring) |
| Loss from operations | −$23.5M | −$14.0M | Opex nearly doubled |
| Net loss | −$25.3M | −$28.8M | per share −$0.08 vs −$0.12 |
| Op. cash burn | −$16.4M | −$14.1M | |
| Weighted-avg shares | 308.7M | 235.9M | +31% YoY dilution |
Drivers: the revenue "beat" and gross-margin flip are real but trivial in dollars; the story Q1 actually tells is opex re-inflating as MicroVision absorbs two acquisitions, with R&D nearly doubling. Cash rose to $46.1M (from $32.4M at YE) — but only because they drew $42.5M from selling investment securities and took $20.7M of new note proceeds, while paying $33.2M for the Luminar assets. Guidance/tone: management raised the framing — reiterated FY2026 revenue of $10–15M, raised gross-margin guide to 35–40%, and lowered cash-burn guidance to ~$60M (from $65–70M) on synergy cuts. Balance-sheet flags: $9.9M inventory write-down in FY2025 and a written-to-zero acquired-backlog intangible (the Ibeo order backlog impaired) tell you the prior pipeline did not convert. Market reaction: despite the "beat," the stock fell from ~$0.61 (Jun 1) to $0.29 (Jun 26), a >50% June drawdown — the market is pricing the financing overhang and reverse-split risk, not the revenue line. Unusual vs. own history: the company is now a distressed-asset acquirer, a strategic departure from the prior decade of organic design-win waiting.
No transcripts on the research-layer shelf (transcripts/ empty), so this is web-derived and labeled. The arc across the last several calls:
Sentiment shift: from defensive-waiting to acquisitive-pivoting. Honest read — the pivot is rational (industrial/defense has a real near-term TAM and shorter sales cycles), but the language is doing heavy lifting against a balance sheet that constrains every option. A reset narrative on a melting share price is the oldest tell in micro-cap.
Western lidar pure-plays. Multiples are with source/date or marked not-sourced — **no multiple is fabricated.** MVIS market cap is; its EV/Sales is an `` off research-layer revenue.
| Company | Ticker | Mkt cap | EV/Sales | P/E | Div yld | 5-yr avg ROE | Source |
|---|---|---|---|---|---|---|---|
| MicroVision | MVIS | ~$96M (Jun 26) | ~80x trailing | n/m (loss) | 0% | deeply negative (net loss every year; accum. deficit $957M) | cap; rev |
| Ouster | OUST | n/a | ~7x fwd sales | n/m | 0% | negative | |
| Aeva | AEVA | n/a | >50x fwd sales | n/m | 0% | negative | |
| Innoviz | INVZ | n/a | n/a | n/m | 0% | negative | |
| Hesai | HSAI | n/a | n/a | n/m | 0% | improving (nearing profitability) |
Read: the whole cohort is unprofitable and richly valued on hope, but MicroVision is the worst-positioned name on revenue scale — Ouster does ~$143M revenue (8x+ Aeva, and ~120x MVIS) at a grounded ~7x sales with <$5M quarterly burn and ~$170M cash; Innoviz is integrated into Mobileye Drive with L3 SoP 2026/27; Hesai has real automotive volume. MVIS trades at a far higher implied EV/Sales than Ouster on a fraction of the revenue and a worse balance sheet. On any revenue-anchored multiple, MVIS is the most expensive lidar name for the least revenue and the most financing risk. The only honest defense of the valuation is option-value-on-the-IP, not multiples.
MVIS is a retail/meme-driven, financing-news-driven stock — its >5% moves cluster on dilution events, squeeze dynamics, and binary "deal" headlines, far more than on fundamentals:
What the market actually reacts to for this name: (1) the share count / financing trajectory, (2) squeeze positioning, (3) any credible automotive design-win or large defense contract (none yet at scale). It is not an earnings-fundamentals stock — there are no earnings. This is the single most important behavioral fact for sizing any position.
Leadership just changed at the top. Sumit Sharma (CEO Feb 2020 → Sep 30 2025; with the company since 2015) was replaced by Glen DeVos, who joined as CTO in April 2025 and became CEO effective Sep 30 2025. The FY2025 10-K thus reports a year run mostly by Sharma but signed into a DeVos regime.
insider-transactions.csv is empty (not sourced on the shelf). Sharma base comp was ~$530K + 100%-of-salary bonus + 1.125M RSUs (2024 agreement) — RSU-heavy comp that dilutes alongside the equity it rewards.Accounting / disclosure risks (all figures ``):
Regulatory findings (required sub-section). Read regulatory/regulatory-findings.md:
"MicroVision" (FTC OR DOJ OR FDA OR CFPB OR consent decree OR settlement OR fine OR penalty) enforcement) surfaced no material regulatory action.For a company at ~$1M revenue with a negative-margin product, an EPS line is meaningless and would be fabricated precision — so the scoreable variable is revenue vs. guidance and runway. Bottom-up from the latest actuals + guidance +:
Inputs (labeled):
Scenario paths (revenue, `` with arithmetic):
No forecast.ts create in the --watchlist loop (per skill rule — only log a Brier forecast on genuine conviction; this is a breadth pass). For the record, the scoreable base claim would be: "MVIS FY2026 revenue < $12M (misses guide midpoint), resolves 2027-03-31" — directionally my lean, but not logged here.
Bull case. MicroVision now owns one of the widest Western lidar IP/product stacks (MEMS + flash + FMCW + ToF, 905→1550nm) after buying the Ibeo, Luminar (IRIS/HALO), and Scantinel assets — much of it for cents on the R&D dollar, out of bankruptcy. A new CEO with real Aptiv automotive pedigree is executing a coherent "fund the automotive marathon with near-term industrial/defense revenue" pivot. Industrial autonomy and defense lidar are genuine, shorter-cycle, higher-margin TAMs with tailwinds (warehouse automation, autonomous mining/hauling, counter-UAS/ground-robotics). If the Western lidar field consolidates to 2–3 survivors and MicroVision is one — or gets acquired for its IP/automotive-grade qualification — equity could re-rate violently off a ~$96M cap. Optionality + ~22% short interest = explosive upside if a catalyst lands.
Bear case (2–3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): the squeeze never came; the reverse split executed and the post-split stock kept sliding as the ATM and converts issued into weakness; FY2026 revenue landed mid-single-digit millions (missed the $10–15M guide); a dilutive raise at a distressed post-split price gutted holders; the IP optionality got realized only via an acqui-hire that paid debt and crumbs to equity.
Are multiples too high? Yes — on any revenue anchor (≈80x trailing / ~50x forward-guide EV/Sales vs. Ouster's ~7x on 120x the revenue), MVIS is the most expensive, least-revenue, worst-balance-sheet lidar name. The valuation is pure option premium.
Contrarian view (what the market refuses to see): the genuinely contrarian take cuts bearish, not bullish — the consensus retail narrative treats MVIS as a coiled short-squeeze + "Lidar 2.0 transformation" story, but the dominant, under-priced reality is that the equity is a financing instrument: every operational "win" is funded by selling more of the company at sub-$1, so good news for the lidar business can still be bad news for the per-share owner. The asymmetric, less-crowded insight is that a reverse split here is a countdown, not a catalyst.
Dismantling the bull case. Where revenue is concentrated: in a handful of sub-$1M customers and an aspirational automotive pipeline — if the one ag/construction customer or the one EU defense customer slips, revenue halves again, as it already has. Why the moat is weaker than bulls think: "widest IP stack" assembled from three companies that failed or distressed (Ibeo bankruptcy, Luminar Chapter 11, Scantinel bargain-purchase) — a portfolio of other people's failures is not obviously a winning hand; if the tech were a durable moat, these assets wouldn't have been for sale at fire-sale prices. Most dangerous competitor bulls underestimate: Hesai (Chinese scale + cost) and Ouster (real $143M revenue, $170M cash, near-breakeven) — both can out-spend and out-ship MicroVision into oblivion while it rations cash; on the OEM side, Innoviz (Mobileye Drive, L3 SoP) is already in a production platform MVIS is still quoting for. Worst capital-allocation / structure: the toxic convertible — zero coupon, conversion at $0.7462 / $1.596 (well below where the stock once traded), monthly forced partial repayments at a 10% premium, a 110%-of-balance minimum-cash covenant, and a holder who can dump converted stock into the market; plus a new $43M note at $0.8819 (61.3M shares) and an open ATM. Assumptions that must hold for today's price: continued capital-markets access at sub-$1, listing maintained through the reverse split, and the industrial/defense ramp actually printing in H2-2026. If growth disappoints 20–30%: essentially irrelevant to a DCF (there's no positive cash flow) but highly relevant to financing — a guide miss closes the equity window and forces worse terms, a reflexive down-spiral. Single permanent-impairment scenario (and plausibility): a financing-driven recapitalization or delisting that wipes most equity value — plausible, not tail-risk, given <12-month cash and the existing structured debt.
A best-in-class MedTech compounder whose 8-9.5% organic engine is intact, but at ~20x forward EPS the stock already prices the cyber-attack recovery as a formality — the bet is that a $375M Q1 air-pocket is timing, not a dent in the franchise.
A genuine top-3 global robotaxi platform finally crossing city-level unit-economics breakeven — but priced for execution it has not yet earned, with a related-party-and-China-permit overhang that the −65% drawdown is screaming about; net-cash floor + founder 540-day lockup make it a WATCHING name to size on proof of fleet-scaling through the permit freeze, not a chase here.
A spine-implant roll-up wearing a robotics badge — the robot is <5% of revenue and a razor-and-blade pull-through, not the story; the real bet is whether mid-single-digit organic growth re-accelerates as NuVasive integration scars heal, at a justified ~16x value-medtech multiple.